Finance and funding: latest news

Finance and funding features

Finance and funding news from aidsmap

More news

Finance and funding news selected from other sources

  • HIV services face cuts in worst hit areas

    Support services for people living with HIV in South London are at risk of being cut, it has been revealed today. The proposed cuts to advice and counselling services will affect people living with HIV in Lambeth, Southwark and Lewisham, where HIV rates are soaring far above the national average.

    16 hours ago | Terrence Higgins Trust
  • With new data, states can better focus HIV prevention for gay, bisexual, and other men who have sex with men

    HIV prevention for MSM has long been complicated by a lack of complete data.Now, Emory University researchers, in collaboration with CDC, have provided that crucial information Exit Disclaimer. The researchers estimated HIV rates for MSM in every state, and in most counties and cities nationwide.

    18 May 2016 | aids.gov
  • Covering Costly HCV Tx: Who Makes that Call?

    Forcing U.S. states to cover pricey treatments for people with the hepatitis C virus (HCV) would cause the Medicaid budget to "explode," according to a Medicaid representative.

    11 May 2016 | MedPage Today HIV/AIDS
  • It’s Time to End Insurance Restrictions on Life-Saving Hepatitis C Treatments

    As consensus on the shortsightedness of insurance restrictions on life-saving hepatitis C treatments continues to build, it’s time for private insurers and Medicaid programs to give all Americans suffering from this devastating disease a chance at a cure.

    10 May 2016 | American Journal of Managed Care
  • Study: Cheaper to cure hepatitis C sooner than later

    Although it would take a huge investment at the outset, treating hepatitis C patients could save $800 billion in the next 20 years and free up treatment for thousands of people with other liver disease.

    10 May 2016 | UPI.com
  • A Way Out of the Dismal Arithmetic of Hepatitis C Treatment

    This special issue of The American Journal of Managed Care presents important new peer-reviewed research about the consequences of this dismal arithmetic of HCV treatment. The papers cover ground ranging from the out-of-pocket costs of a DAA treatment course to the real-world consequences—both economic and clinical—of failing to treat.

    10 May 2016 | American Journal of Managed Care
  • 'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier

    Merck & Co. has yet to report first-quarter earnings, so industry watchers still don’t know exactly how much market share the company’s new hep C combo treatment, Zepatier, has scored since winning approval in late January. But so far, comments from its competitors suggest it’s doing pretty well for itself.

    03 May 2016 | Fierce Pharma
  • New York Insurers to Change Coverage of Hepatitis C Drugs

    Seven health-insurance companies in New York will change their criteria for covering costly drugs that cure chronic hepatitis C under the terms of agreements with the office of State Attorney General Eric Schneiderman.

    26 April 2016 | Wall Street Journal
  • HIV PrEP currently too pricey to justify use in people who inject drugs

    The model suggested that over 20 years, enrolling a quarter of HIV uninfected injection drug users in a PrEP + screening + ART program would be the optimal approach for reducing HIV infection. However, at current drug prices this approach would cost the U.S. an additional $44 billion, which is equivalent to annually spending 10 percent of the current federal budget for domestic HIV/AIDS on PrEP for people who inject drugs.

    26 April 2016 | Medical Xpress
  • Kenya’s new policy on domestic financing of HIV research

    In Kenya an ambitious new target to increase national funding of HIV research sees the government expecting to raise about USD109 million from local sources over the next five years.

    18 April 2016 | Key Correspondents
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.